MIRUM PHARMACEUTICALS INC (MIRM) Stock News
NASDAQ:MIRM - Nasdaq - US6047491013 - Common Stock - Currency: USD
MIRM Latest News, Press Relases and Analysis
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
UK's Thames Water set for over $13.5 billion rescue deal by Silver Point and Elliott, Bloomberg News reports
The rescue package will provide an equity boost of between 3 billion pounds and 4 billion pounds to stabilize the utility's finances, according to the report. "The Creditors have submitted a detailed long-term turnaround plan that will fix the root causes of Thames Water's problems, restore its balance sheet, rebuild customer trust and fix the fundamentals of the business once and for all," a spokesperson for the creditors, which include Silver Point Capital and Elliott, said in an emailed statement to Reuters.
Why Is Mirum Pharmaceuticals (MIRM) Down 1.3% Since Last Earnings Report?
Mirum Pharmaceuticals (MIRM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Mentions: MRNA
Mirum Pharmaceuticals Appoints Doug Sheehy, JD, as Chief Legal Officer
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Volixibat Data from Mirum’s VANTAGE PBC Study Showcased at EASL
Mirum's Q1 Earnings Beat Estimates, 2025 Revenue View Raised
MIRM reports better-than-expected first-quarter 2025 results. The company raises its 2025 revenue guidance. Shares rise.
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q1 Loss, Tops Revenue Estimates
Mirum Pharmaceuticals (MIRM) delivered earnings and revenue surprises of 23.08% and 13.32%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: SPRO
Mirum Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
Cytokinetics (CYTK) Reports Q1 Loss, Lags Revenue Estimates
Cytokinetics (CYTK) delivered earnings and revenue surprises of 3.55% and 26.49%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: CYTK
Tango Therapeutics, Inc. (TNGX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Tango Therapeutics (TNGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mentions: TNGX
Mirum Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025
Mirum Pharmaceuticals to Present Data at Upcoming Medical Congresses
FDA Approves Mirum Pharmaceuticals’ Drug For Rare Liver Disease Patients In Tablet Form: Retail Stays Bullish
Livmarli tablets will be available in June through Mirum Access Plus pharmacy.
Mirum’s LIVMARLI Now FDA Approved in Tablet Formulation
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Is Verint Systems (VRNT) the Best Affordable Tech Stock to Buy According to Analysts?
We recently published a list of 12 Best Affordable Tech Stocks to Buy According to Analysts. In this article, we are going to take a look at where Verint Systems Inc. (NASDAQ:VRNT) stands against other best affordable tech stocks to buy according to analysts. Stock affordability can be assessed in multiple ways. The most common […]
LIVMARLI Now Approved in Japan for ALGS and PFIC
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update
Mirum’s CTEXLI™ (chenodiol) Tablets Receives FDA Approval for Treatment of Cerebrotendinous Xanthomatosis (CTX)
Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2024 Financial Results and Host Conference Call on February 26, 2025
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mirum Pharmaceuticals Announces Preliminary Unaudited 2024 Net Product Sales and Cash Balance and Provides Corporate Updates
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mirum Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mirum Pharmaceuticals to Showcase Data from its LIVMARLI and Volixibat Clinical Programs at AASLD’s The Liver Meeting
